Startup Rise America News’ Post

INOVIQ Ltd (ASX:IIQ) is pleased to announce that it has successfully completed an A$7 million placement to institutional and sophisticated investors at A$0.50 per share. Funds raised will be used to advance commercialisation of EXO-NET® research tools and SubB2M diagnostics, progress development of pipeline diagnostics and expedite research of high-value cancer therapeutics, enabling the Company to progress its pipeline and bring new products to market. Over the next 12-months, INOVIQ expects to achieve the following milestones: ◼ Revenue growth from sales of EXO-NET exosome isolation tools (through our Promega partnership and direct sales/services); ◼ Exosome diagnostic biomarker validation for ovarian cancer; ◼ Exosome diagnostic development agreement (collaborator/partner); ◼ Exosome therapeutic in vitro data for breast cancer; and ◼ Commercial partner for SubB2M test for monitoring breast cancer. To read the announcement go to: https://lnkd.in/gRSjY9mw To read the investor presentation go to: https://lnkd.in/gx-RWae7 #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Therapeutics #Diagnostics #CancerResearch #LifeSciences

🚀 Exciting News! 🚀 We are thrilled to announce that our portfolio company, iOnctura, has closed a EUR 80 million Series B round! Led by Syncona Limited and the European Investment Council, this funding will drive the late-stage development of treatments for hard-to-treat cancers. Since our initial investment in 2019, iOnctura's team has delivered exceptional proof-of-concept data for its drug candidates, roginolisib and cambritaxestat, in rare tumors with high unmet needs. With this new financing, roginolisib will be tested in broader trials for uveal melanoma, non-small cell lung cancer, and primary myelofibrosis, while cambritaxestat will advance for fibrotic cancers like metastatic pancreatic cancer. We are excited to welcome new investors and continue supporting iOnctura as it brings these critical treatments closer to patients in need. #Biotech #Investment #CancerTreatment #Pharma #Innovation #HealthTech #SeriesBRound #iOnctura #EuropeanInvestmentCouncil #Inkef

🔦 Venture Champions #Challenge winner #spotlight: Tropocan Inc. 🎉 #Congratulations again to Tropocan Inc., founded by Dr. Evgenii Boriushkin being one of the #winners in the #Biotech Track of the 2024 VC Challenge! 🏆 Currently in the #oncology space there are few cancer drugs that can reach the brain directly. Enter Tropocan Inc., a startup focused on developing a new brain permeable #therapy to treat primary #brain tumors and brain metastates for breast and lung cancer. Through the #development of a small but powerful molecule, Tropocan hopes to optimize the effectiveness of existing anti-cancer drugs, transforming the oncology and #pharmeceutical #industry by changing how current #anticancer drugs can be utilized. 🧠 💸 Tropocan Inc. will be receiving $5,000 to fund their path to #market with continued #mentorship and assistance from the #LIHTI team. 👏 #VentureChampions #cancertreatment #braincancer #cancertherapy #LongIsland #incubator #innovation #startup

Announcement: New Pitching Start-ups at Global Investor Forum! 🚀   🎉 We're thrilled to announce that Johan Pijnenborg of GlycoTherapeutics will be pitching at Global Investor Forum! 🌍✨    About GlycoTherapeutics: GlycoTherapeutics is a drug development startup committed to overcome the efficacy limitations of current cancer immunotherapies. Less than 50% of individuals with cancer receiving immunotherapy obtain a durable response, which is partly due to glycobiology processes that suppress the immune system. Based on over a decade of research, GlycoTherapeutics’ proprietary solution targets these processes by disrupting the interaction of glycans (sugars) that are responsible for immune evasion to maximize the potential of immunotherapy.   Read more about Johan Pijnenborg & GlycoTherapeutics https://lnkd.in/e8h5wnSp   👏 Join us: Are you a start-up wanted to pitch your company for investors and other key players in the industry? Or are you an investor looking to meet innovative companies? Join us at I4H Global Investor Forum.   Save the date 🗓️ 27 March 2024 📍Loyens & Loeff office Rotterdam 🔗https://lnkd.in/eGyCCcH

Angiex Inc. is pioneering the development of antibody-drug conjugate (ADC) therapies that attack cancer three ways: by killing cancer cells, by activating immunity against tumors, and by depriving tumors of their blood supply. The flagship drug, AGX101, offers potential for universal efficacy against all solid cancers with no known resistance mechanism. Thanks to exceptional tumor homing that fulfills Paul Ehrlich’s desire for a “magic bullet” that strikes only at tumors, Angiex's therapeutic solutions are notably safe at therapeutic doses. With AGX101 now in Phase 1 clinical trials, Angiex offers a highly attractive investment opportunity at a pre money valuation of $8 million. Comparable ADC companies with lesser potential have transacted for billions, making Angiex's valuation and technology exceptional in the oncology sector. 💰Investment Offering Angiex is finalising its Series Seed+ equity financing round, aiming to raise $14 million on an $8 million pre money valuation. $7.4 million has been completed in the first closing of December 22, 2023, and $6.6 million remains to be raised. This investment will support the completion of Phase 1 clinical trials, leveraging the company’s promising valuation growth potential. Register your interest with Angiex here: https://lnkd.in/gCP5xPzT Steve Torso #cancertherapies #biotech #cancertreatment #clinicaltrial #oncology #investmentopportunity #capitalraising #vc #privateequity #angelinvesting #privatecapital #hnw 

ATTN #BIO2024: Today at 2:30 pm, our CEO, Bob Linke, gives a company presentation about OSM-0205, our lead product. We look forward to providing an update on our plans for OSM-0205, which is poised to initiate clinical development later this year. OSM-0205 is a preventative treatment to help patients avoid the painful and debilitating effects of chemotherapy-induced peripheral neuropathy (CIPN), common amongst taxane-based chemotherapies, including the leading breast cancer chemotherapy treatment. CIPN affects as many as 80% of these cancer patients and can significantly impact both quality of life and survival. Stop by to see our company presentation or request a meeting with our CEO, Bob Linke through, the Biotechnology Innovation Organization (BIO) One-on-One Partnering™ System: https://lnkd.in/eEDtKaAK #oncology #biotech #investors

𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐖𝐞𝐞𝐤 𝐟𝐨𝐫 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐅𝐮𝐧𝐝𝐢𝐧𝐠: 400 Million secured with an exciting IPO 👇 👉 Cartherics Pty Ltd, successfully secured over AU$15 million in an oversubscribed funding round. This capital for the Melbourne company will support clinical trials for CTH-401, a cell therapy targeting ovarian cancer. ➡️  Enara Bio, located in Oxford, has closed a $32.5 million Series B financing round. Led by Pfizer Ventures and M Ventures, this funding will advance their TCR-based immunotherapies focused on novel Dark Antigens in solid tumours. 👉 Resolution Therapeutics has raised £63.5 million ($85 million) in Series B financing. This UK cell therapy biotech will use the funding to facilitate the advancement of their macrophage therapy, RTX001, into clinical trials for end-stage liver disease. ➡️  Zephyrm Bioscience is set for a successful IPO to fund Phase 3 trials of their cell therapy ZH901, aimed at treating lung conditions and graft-versus-host disease. They have also raised 258 million Chinese yuan ($37 million) to support their development efforts. Excellent to see investments pouring in the U.K, APAC and even Australia. What do you think the impact of these investments will for cell therapy? #celltherapy #genetherapy #cellandgenetherapy #CGTweekly

Thanks, Spencer Knight, for sharing this. Might the #BiotechFunding atmosphere be making a sustainable turn? Certainly hope so! #TheTD2Difference #Bench2Bedside #CART #CellTherapy #CancerTherapeuticDevelopment #Preclinical #RegulatoryConsulting #ClinicalTrialManagement #TrialStartup

#ICYMI Matthew Herper of STAT sat down with our CEO, Dr. J. Jean Cui, to learn more about her story and mission to develop effective therapeutics that tackle drug resistance. Discover how Dr. Cui and BlossomHill are applying human intelligence and creativity to drug design with the goal of extending survival and improving quality of life for #cancer patients. Read the full article here: https://bit.ly/49NRCLA     #precisionmedicine  

TORL BioTherapeutics, LLC, a pioneering biotech company dedicated to revolutionizing cancer treatment, has just closed an impressive $158 million Series B-2 financing round, surpassing expectations! 🚀 🌟 Led by Deep Track Capital and joined by esteemed investors like RA Capital Management and Perceptive Advisors, this oversubscribed funding marks a significant milestone for TORL. 💼 With total funding now exceeding $350 million, TORL is poised to advance its groundbreaking immunotherapy programs, including the promising TORL-1-23 ADC for CLDN 6+ tumors. 🎗️ 💭 This investment underscores the growing confidence and enthusiasm in the biotechnology sector, highlighting the immense potential for innovation and breakthroughs in the fight against cancer. 💪 #BiotechInnovation #CancerResearch #UnioSearch #UnitedinSuccess 🧬🔬